In short
Clinical trials investigating "Zinc Sulphate Heptahydrate" are not listed in the source data, but the provided trials study related nutrition support after major surgery. These studies look at outcomes such as muscle loss and infection risk in adults after oesophagectomy or emergency abdominal surgery.
Key points
- Two authorised Phase 3 trials in the source data study nutrition support after major surgery. One trial follows adults after oesophagectomy and measures muscle size loss on CT scan over 10 days. The other trial studies adults after major emergency abdominal surgery and measures infectious complications during the hospital stay. Both studies compare different parenteral nutrition approaches, which means nutrition given through a vein. The source data does not list any clinical trial directly investigating Zinc Sulphate Heptahydrate.
Trial overview
The source data does not list a trial directly studying Zinc Sulphate Heptahydrate. Instead, it lists two authorised interventional studies about nutrition support after major surgery.
Both studies are Phase 3 trials, which means they are testing treatments in larger groups of patients and comparing outcomes in real clinical settings.
Nutrition after oesophagectomy
One trial is titled Route of nutrition and muscle wasting after oesophagectomy. It is a Phase 3 interventional study with 38 planned participants and an authorised status.
This study aims to understand how the route of nutrition affects cachexia, which means severe weight and muscle loss, after oesophagectomy.
The intervention listed is SmofKabiven emulsion for infusion, which is given by parenteral use, meaning through a vein rather than by mouth.
Early versus postponed supplementary parenteral nutrition
The second trial is titled Early versus postponed supplementary parenteral nutrition after major emergency abdominal surgery. It is also a Phase 3 interventional study and is authorised, with 342 planned participants.
This study compares early and postponed supplementary parenteral nutrition after major emergency abdominal surgery. The goal is to see whether one approach lowers the risk of nosocomial infections, which are infections that happen during a hospital stay.
The interventions listed are SmofKabiven Perifer and SmofKabiven, both given by infusion.
What the trials measure
The main outcome in the oesophagectomy study is the mean difference in muscle size on CT scan from before surgery to 10 days after surgery.
This outcome helps researchers see whether nutrition route is linked to less muscle loss after surgery.
The main outcome in the emergency abdominal surgery study is a reduction in the rate of infectious complications during admission.
This outcome focuses on whether the timing of supplementary parenteral nutrition affects infection risk while the patient is in hospital.
Who may take part
The source data shows that the target populations are adults after oesophagectomy and adults after major emergency abdominal surgery.
No additional eligibility details are provided in the source data, such as age limits, lab tests, or medical exclusions.
Why Phase 3 matters
Phase 3 studies are usually used to compare treatment approaches in larger groups and measure important health outcomes.
In these two trials, the researchers are not only looking at whether nutrition support can help, but also at specific recovery results such as muscle size and infection rates.